Vanda Pharmaceuticals Inc.  

(Public, NASDAQ:VNDA)   Watch this stock  
Find more results for VNDA
12.20
0.00 (0.00%)
Jan 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 8.34 - 19.25
Open     -
Vol / Avg. 0.00/856,100.00
Mkt cap 483.74M
P/E     -
Div/yield     -
EPS -1.69
Shares 39.65M
Beta 1.91
Inst. own 111%
Feb 11, 2015
Q4 2014 Vanda Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Dec 23, 2014
Vanda Pharmaceuticals Inc. Commercialization plans for Fanapt Conference Call - Webcast
Dec 3, 2014
Vanda Pharmaceuticals Inc at Piper Jaffray Healthcare Conference - Webcast
Nov 18, 2014
Vanda Pharmaceuticals Inc at Stifel Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -9.65% -59.79%
Operating margin -9.80% -60.21%
EBITD margin - -54.53%
Return on average assets -6.92% -14.53%
Return on average equity -587.24% -74.98%
Employees 53 -
CDP Score - -

Address

Suite 300E, 2200 Pennsylvania Ave NW
WASHINGTON, DC 20037
United States - Map
+1-202-7343400 (Phone)
+1-202-2961450 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Vanda Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of products for the treatment of central nervous system disorders. The Company�s product portfolio includes: HETLIOZ (tasimelteon), a product for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24); Fanapt (iloperidone), a product for the treatment of schizophrenia, the oral formulation; and VLY-686 (tradipitant), a small molecule neurokinin-1 receptor (NK-1R) antagonist. . Novartis has exclusive commercialization rights to all formulations of Fanapt in the United States and Canada. Novartis is responsible for the further clinical development activities in the United States and Canada.

Officers and directors

Howard H. Pien Independent Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Mihael H. Polymeropoulos M.D. President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
James Patrick Kelly Chief Financial Officer, Senior Vice President, Treasurer, Secretary
Age: 48
Bio & Compensation  - Reuters
Paolo Baroldi M.D., Ph.D. Senior Vice President, Chief Medical Officer
Age: 63
Bio & Compensation  - Reuters
Michael F. Cola Independent Director
Age: 54
Bio & Compensation  - Reuters
Richard W. Dugan Independent Director
Age: 72
Bio & Compensation  - Reuters
Steven K. Galson M.D. Independent Director
Age: 57
Bio & Compensation  - Reuters
Vincent J. Milano Independent Director
Age: 51
Bio & Compensation  - Reuters
H. Thomas Watkins Independent Director
Age: 61
Bio & Compensation  - Reuters